ArticleEuropean heart journal2025
C-reactive protein and cardiovascular risk in the general population.
Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights.Cardiovascular drugs and therapy · 2026Pooled it
- Multi-ancestry genome-wide association study of serum creatine kinase implicates myopathy genes and muscle pathways.EBioMedicine · 2026Pooled it
- Cardiovascular risk estimation using the steno type 1 risk engine in Brazilian individuals with type 1 diabetes: a multicenter cross-sectional study.Clinics (Sao Paulo, Brazil) · 2026Article
- Sex-specific associations of the triglyceride-glucose index with systemic inflammation and arterial stiffness in adults with normal glucose and triglyceride levels.Atherosclerosis plus · 2026Article
- Environmental Toxic Metals and Metalloids Exposure and Cardiovascular Health: Current Evidence from Oxidative Stress and Inflammatory Biomarkers as Indicators of Subclinical Cardiovascular Effects.Antioxidants (Basel, Switzerland) · 2026Review
- Circulating Cardiovascular Biomarkers 1-3 Years Following Hypertensive Pregnancy Disorders: Associations With Postpartum Cardiovascular Structure and Function.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies.Immunological reviews · 2026Review
- Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohort.American journal of preventive cardiology · 2026Article
- Article
- Urinary carnosine links diet quality with one-carbon and lipid metabolism: insights from an interpretive framework for imidazole metabolites.European journal of nutrition · 2026Article
- Longitudinal changes and cumulative exposure of cardiometabolic index predict cardiovascular disease risk in middle-aged and older adults: a national prospective cohort study.BMC cardiovascular disorders · 2026Article
- Growth differentiation factor-15 and the incidence, bidirectional progression, and risk prediction of atherosclerotic cardiovascular disease and metabolic dysfunction-associated steatotic liver disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3.Cardiovascular diabetology · 2026Article
- Repeat CRP measurements and incident myocardial infarction.American journal of preventive cardiology · 2026Article
- Estimating residual inflammatory risk: Further insights into repeat hsCRP Testing from the UK BioBank.American journal of preventive cardiology · 2026Article
- Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in metabolic-dysfunction associated steatotic liver disease: evidence from two cohort studies.Cardiovascular diabetology · 2026Observational
- Significant correlations between blood lipids, cytokines, and C-reactive protein in healthy humans.Lipids in health and disease · 2026Article
- Interaction between high-sensitivity C-reactive protein and mean platelet volume for 1-year major adverse cardiovascular events in stable coronary artery disease.Scientific reports · 2026Article
- Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.International journal of molecular sciences · 2026Review
- Inflammatory responses driven by neutrophil extracellular traps in cardiovascular diseases: molecular mechanisms, emerging biomarkers, and therapeutic targets.Frontiers in immunology · 2026Review
- Silent inflammation: a hidden cause of liver fibrosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
BACKGROUND AND
aimsHigh-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker to identify patients at residual risk.
methodsIn this population-based study, hsCRP was measured in 448 653 UK Biobank participants without known ASCVD. The association of hsCRP with major adverse cardiovascular events (MACE), CV death and all-cause death was assessed using Cox proportional hazards models.
resultsThe cohort had a median age of 57 years, 55.4% were female, and median hsCRP levels were 1.32 mg/L. A repeat hsCRP measurement in 15 967 participants after 4.4 years showed long-term stability. In covariate-adjusted models individuals with hsCRP levels >3 mg/L had a 34% higher risk of MACE, a 61% and 54% increased risk of CV death and all-cause death compared to those with hsCRP <1 mg/L. Subjects with hsCRP levels ≥2 mg/L vs <2 mg/L had a 22% increased risk of MACE, and a 37% and 34% higher risk of CV death and all-cause death. The association of hsCRP with all endpoints was consistent across subgroups. Predictive performance of hsCRP ranked above conventional risk factors. Integration of hsCRP improved SCORE2 and provided a total net reclassification improvement of 14.1% for prediction of MACE.
conclusionsThese data confirm hsCRP as a clinically relevant predictor of CV events in individuals without known ASCVD and support its assessment in primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.